Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2013-01-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth or by blocking blood flow to the cancer. Drugs used in chemotherapy,
such as cytarabine, work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Giving sorafenib together with
cytarabine may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib
together with cytarabine and to see how well it works in treating older patients with acute
myeloid leukemia or high-risk myelodysplastic syndrome.